乳糖酸修饰的介孔二氧化硅纳米粒子靶向肝癌研究  

Study on mesoporous silica nanoparticles modified with lactose acid targeting liver cancer

作　　者：王镀津 魏莉平 汪宏良 Wang Dujin;Wei Liping;Wang Hongliang(Department of Clinical Laboratory,Huangshi Central Hospital of Edong Healthcare Group(Affiliated Hospital of Hubei Polytechnic University),Hubei Huangshi 435000,China;Department of Clinical Laboratory,Maternal and Child Health Care Hospital,Edong Healthcare Group,Hubei Huangshi 435000,China)

机构地区：[1]鄂东医疗集团市中心医院(湖北理工学院附属医院)检验科,湖北黄石435000 [2]鄂东医疗集团市妇幼保健院检验科,湖北黄石435000

出　　处：《现代肿瘤医学》2019年第19期3403-3409,共7页Journal of Modern Oncology

摘　　要：目的:合成一种具有肝癌特异性的纳米药物载体,实现对肝癌细胞靶向释放化疗药物阿霉素(doxorubicin,DOX)。方法:本研究将具有肝癌特异性的配体乳糖酸(lactobionic acid,LA)修饰到介孔二氧化硅(mesoporous silica nanoparticles,MSN)表面,合成具有肝癌靶向作用的纳米载体LA-MSN,然后用LA-MSN负载化疗药物阿霉素,形成具有肝癌特异性靶向杀伤作用的纳米药物DOX/LA-MSN。结果:细胞荧光成像以及细胞电子显微镜实验显示乳糖酸具有良好的肝癌细胞靶向作用并能有效转运DOX/LA-MSN纳米药物进入肝癌细胞。体外杀伤实验显示DOX/LA-MSN纳米药物在体外能够有效杀伤HepG2肝癌细胞,小动物活体成像实验表明LA-MSN纳米药物具有在体内靶向实体肝癌的能力。结论:DOX/LA-MSN纳米药物能够有效避免阿霉素药物非特异性的缺点,实现对肝癌靶向治疗,是一种具有良好应用前景的纳米药物载体。Objective:To develop a multifunctional nanodrug carrier specifically targeting the tumor cell membrane via blood circulation after intravenous administration to realize the site-oriented release of chemical drugs with DNA toxicity to improve therapeutic effects for solid tumors.Methods:Lactose(LA),a hepatoma-specific targeting ligands,was modified to the surface of mesoporous silica nanoparticles(MSN) to synthesize LA-MSN.A vehicle used to achieve the site-specific delivery of doxorubicin(DOX).Results:The study indicated that LA had an evident tumor cell membrane transport effect.DOX/LA-MSN,a targeting nanomaterial,could release DOX quickly at pH 5.0,and the release amount in 72 hours was more than 80% of the total release amount.Conclusion:LA-MSN,a liver cancer-specific targeting vehicle,could transport DOX in vitro,and overcome its nonspecificity for cells,offering a promising strategy.

关 键 词：乳糖酸 介孔二氧化硅 阿霉素 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]